表紙
市場調查報告書
商品編碼
958321

新的藥物遞輸系統(NDDS)的全球市場

Novel Drug Delivery Systems (NDDS)

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 492 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球新藥物遞輸系統(NDDS)的市場規模在分析期間(2020年∼2027年)內預計將以19.7%的年複合成長率增長,從2020年的77億美元到2027年達到272億美元。本報告分析市場區隔之一的奈米粒子部門在分析期間結束前預測將以19%的年率增長,達到232億美元。

本報告提供全球新藥物遞輸系統(NDDS)市場的相關調查,提供市場佔有率,趨勢和預測,成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Abbott Laboratories
  • AstraZeneca PLC
  • Bayer HealthCare Pharmaceuticals
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.

目錄

I. 簡介,調查手法,調查範圍

II. 摘要整理

  • 市場概要
    • 競爭的市場佔有率
    • 競爭的市場佔有率方案
    • Covid-19的影響和即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 各地區市場分析
  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 其他地區

IV. 競爭

  • 簡介公司總數:46公司
目錄
Product Code: MCP13631

What`s New for 2022?

» Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

» Online interactive peer-to-peer collaborative bespoke updates

» Access to our digital archives and MarketGlass Research Platform

» Complimentary updates for one year

Global Novel Drug Delivery Systems (NDDS) Market to Reach US$28.1 Billion by the Year 2026

NDDS refer to new approaches, technologies, formulation, and systems used for the transportation of a pharmaceutical compound inside the body for safely achieving its desired pharmacological effects. Growth in the global market is set to be primarily driven by the benefits offered by controlled-release drug delivery systems, including reduced treatment cost, lower side effects, and enhanced therapeutic efficacy. The growing adoption of controlled-release drugs as a standard treatment for various diseases, rising awareness and demand for advanced products among physicians, and increasing prescription of controlled-release products are some of the key factors that are likely to bolster the market growth in the near future. Further, presence of several in-vivo biological barriers that impacts the drug`s stability, absorption, and bioavailability are opening lucrative opportunities for the adoption of controlled-release drug delivery systems. The adoption of controlled-release drug delivery systems is also being propelled by the rapidly growing pediatric and geriatric population, owing to high incidence of non-adherence to prescription drugs in these age-groups. Nanotechnology has come to the fore to further enhance the relevance of continuous improvisation and innovation of NDDS, especially for administering active agents. Several terminal diseases such as immunodeficiency diseases and cancers require controlled and targeted therapy with minimum side effects, and for these systems, nanocarrier-based systems deliver a better therapeutic effect at the target site. Currently, the pharmaceutical industry is preparing for widespread adoption of nanoparticles, which represents a crucial element in advanced nanotechnology-enabled delivery systems.

Amid the COVID-19 crisis, the global market for Novel Drug Delivery Systems (NDDS) estimated at US$9 Billion in the year 2020, is projected to reach a revised size of US$28.1 Billion by 2026, growing at a CAGR of 20.8% over the analysis period. Nanoparticles, one of the segments analyzed in the report, is projected to grow at a 20.3% CAGR to reach US$27.2 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Embolization Particles segment is readjusted to a revised 22.9% CAGR for the next 7-year period. This segment currently accounts for a 17.3% share of the global Novel Drug Delivery Systems (NDDS) market. The rising uptake of nanotechnology and its various concepts including nanocarriers in novel drug delivery mechanisms is driving growth in the Nanoparticles segment. The use of nanoparticles in delivering drugs to cancer cells with minimum damage to healthy cells is the most promising application of nanotechnology in drug delivery currently under development.

The U.S. Market is Estimated at $4 Billion in 2021, While China is Forecast to Reach $2.9 Billion by 2026

The Novel Drug Delivery Systems (NDDS) market in the U.S. is estimated at US$4 Billion in the year 2021. The country currently accounts for a 37.8% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$2.9 Billion in the year 2026 trailing a CAGR of 25.7% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 18% and 19.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 19.5% CAGR while Rest of European market (as defined in the study) will reach US$3.7 Billion by the end of the analysis period.

Select Competitors (Total 238 Featured) -

  • AstraZeneca PLC
  • Boston Scientific Corporation
  • Cospheric LLC
  • EmboMedics, Inc.
  • F. Hoffmann-La Roche AG
  • Merit Medical Systems, Inc.
  • Mo-Sci Corporation
  • Polysciences, Inc.
  • Sirtex Medical Inc.
  • Terumo Medical Corporation

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Novel Drug Delivery Systems (NDDS) - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
    • 2020: A Year of Disruption & Transformation
    • As the Race between the Virus & Vaccines Intensifies, Where is the World Economy Headed in 2021
    • World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
    • An Insight into Pandemic Impact on Pharmaceuticals Industry
    • COVID-19 & Other Factors Shift Focus to Different Drug Delivery Approaches
    • Novel Drug Delivery Systems Gain Interest Amid the Fight Against COVID-19
    • Nanomaterial-enabled Novel Drug Delivery Systems Gain Interest in Vaccine Development
    • Novel Drug Delivery System (NDDS): A Prelude
    • Versatile Benefits of NDDS Drive Companies to Embrace the Drug Delivery Approach
    • Patient Compliance: A Key Reason Garnering Interest in NDD
    • Regulatory Process for Novel Drug Delivery Systems
    • A Look into Current Areas of Research in Drug Delivery
    • Market Outlook
    • Nanotechnology-Enabled Drug Delivery: Primary Challenges
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Nanotechnology Bolsters Demand for NDDS
    • Prospects Remain Encouraging
    • Microfluidics Mediated NDDS Set to Make Gains
    • Nanocarriers Enable Targeted Drug Delivery Systems to Improve Therapeutic Outcomes
    • Advanced Liposomes Enable Low Soluble Drugs to Achieve Targeted Delivery
    • List of Marketed Liposome-Based Clinical Products Classified by Therapeutic Areas
    • Liposomes-based Drug Delivery Systems to touch Diverse Areas of Modern Medicine
    • Dendrimers as Ideal Drug Delivery Agents
    • List of Commercially Available Dendrimeric Products by Application Area
    • High Drug Loading Capacity of PAMAM Dendrimers Bodes Well for Targeted Drug Delivery Systems
    • Oral Thin Films Enhance NDDS Domain
    • Nanotechnology-Enabled Drug Delivery Opens New Horizons to Improve Cancer Treatments
    • Rising Cancer Incidence Drives Focus onto Novel Drug Delivery Mechanisms
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Number of New Cancer Cases and Deaths (in Million) by Region for 2020
    • Global Breakdown of Total Number of Cancer Cases by Type: 2020
    • Novel Drug Delivery System Emerges as a Potential Treatment for Pediatric Brain Tumors
    • Uptrend in Gene Therapy Market Augurs Well for Market Growth
    • Global Gene Therapy Market in US$ Million: 2020, 20223 and 2024
    • Adeno-Associated Virus Vectors: A Leading Platform for Gene Therapy
    • Application of Nanotechnology-based Drug Delivery Systems for CVD Treatment
    • Global Annual Medical Cost of CVD in US$ Billion (2020-2030)
    • NDD for Antimicrobial Drugs
    • List of Select Nanotechnology-based Antimicrobial Drugs in Clinical Use
    • Nanotechnology Opens New Avenues in Antiretroviral Therapy
    • Demonstrated Activity of Select Nanotechnology-Delivered Antiretroviral Therapies
    • Novel Drug Delivery System Exhibits Potential to Target HIV Reservoirs
    • Global HIV Prevalence Seeks Need for Novel Drug Delivery Systems: Number of People Living with AIDs (in Thousands) by Region for 2020
    • Novel Drug Delivery Systems for CNS Therapeutics
    • Novel Drug and a New Delivery Method for Restoring Brain Cells in People Suffering from PD
    • Nanotechnology Powers Next Wave of Change for Neglected Tropical Diseases' Treatment
    • Novel Drug Delivery Systems Hold Edge over Existing Therapies for Diabetic Retinopathy
    • Exciting Immunology Developments Involving Graphene-based Nanomaterials
    • Nanotechnology-Based Strategies for siRNA Grows in Popularity
    • Nanoemulsions Begin to Make a Mark
    • Inorganic Nanocarriers Facilitate High Payload Capacity and Co-Delivery Platforms for MDR Cancer Therapy
    • Solid Lipid Nanoparticles Provide Increased Physical Stability in Targeted Drug Delivery
    • Recent Advancements in Polymeric Drug Delivery Systems
    • Pulmonary Delivery of Nanoparticle-Based Drugs Receives Increased Interest
    • Inhalable Liposome Formulations Attract Research Interest in Pulmonary Delivery
    • SLNs in Pulmonary Delivery of Drugs
    • Other Nanocarriers in Pulmonary Delivery
    • Increasing Importance of Gold Nanoparticles in Targeted Drug Administration
    • Gold Nanoparticles Open New Avenues in Combinatorial Cancer Therapy
    • Consistent Rise in Healthcare Spending Worldwide to Drive Market Opportunities
    • World Healthcare Expenditure (In US$ Trillion) for the Years for 2017, 2019, 2021 and 2023
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2021 & 2027
    • TABLE 3: World Recent Past, Current & Future Analysis for Nanoparticles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 4: World 7-Year Perspective for Nanoparticles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
    • TABLE 5: World Recent Past, Current & Future Analysis for Embolization Particles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 6: World 7-Year Perspective for Embolization Particles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • Novel Drug Delivery Systems (NDDS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
    • TABLE 7: USA Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 8: USA 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
  • CANADA
    • TABLE 9: Canada Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 10: Canada 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
  • JAPAN
    • Novel Drug Delivery Systems (NDDS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
    • TABLE 11: Japan Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 12: Japan 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
  • CHINA
    • Novel Drug Delivery Systems (NDDS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
    • TABLE 13: China Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 14: China 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
  • EUROPE
    • Novel Drug Delivery Systems (NDDS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
    • TABLE 15: Europe Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 16: Europe 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2021 & 2027
    • TABLE 17: Europe Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 18: Europe 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
  • FRANCE
    • Novel Drug Delivery Systems (NDDS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
    • TABLE 19: France Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 20: France 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
  • GERMANY
    • Novel Drug Delivery Systems (NDDS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
    • TABLE 21: Germany Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 22: Germany 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
  • ITALY
    • TABLE 23: Italy Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 24: Italy 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
  • UNITED KINGDOM
    • Novel Drug Delivery Systems (NDDS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
    • TABLE 25: UK Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: UK 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
  • REST OF EUROPE
    • TABLE 27: Rest of Europe Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 28: Rest of Europe 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
  • ASIA-PACIFIC
    • Novel Drug Delivery Systems (NDDS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
    • TABLE 29: Asia-Pacific Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 30: Asia-Pacific 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
  • REST OF WORLD
    • TABLE 31: Rest of World Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Rest of World 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027

IV. COMPETITION

  • Total Companies Profiled: 238